Delay Discounting as a Potential Therapeutic Target for Weight Loss in Breast Cancer Survivors
Jasmine Sukumar(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Jeffrey S. Stein(Biomedical Research Institute), Jennifer E. Vaughn(The Ohio State University), Allison N. Tegge(Biomedical Research Institute), Maryam B. Lustberg(Yale Cancer Center), Sagar Sardesai(The Ohio State University)
Cited by 12
Related Papers
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2014|1.2k
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update
|Journal of Clinical Oncology|2020|1.1k
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship
|Nature Reviews Clinical Oncology|2023|296
Triple-negative breast cancer: promising prognostic biomarkers currently in development
|Expert Review of Anticancer Therapy|2020|236